Latest Regulation News

Barton Gold Holdings has secured new exploration tenements for its Wudinna Gold Project, marking a pioneering M&A deal under South Australia’s updated mining regulations. This milestone strengthens Barton’s foothold in the region and sets a fresh precedent for future mining investments.

BlackRock Investment Management (Australia) Limited has announced the Distribution Reinvestment Plan (DRP) prices for three major Australian iShares ETFs for the July 2025 distribution period, alongside important investor compliance reminders.

The NSW Government has postponed the planned reduction of the daily cash limit for gaming customers at The Star Sydney, keeping the $5,000 cap in place until August 2027 under strict monitoring conditions.

Vitrafy Life Sciences reported a 75% increase in FY25 sales driven by aquaculture and human health sectors, progressing its cryopreservation technology towards commercialisation in both unregulated and regulated markets in FY26.

Horseshoe Metals advances its Horseshoe Lights copper-gold project with mining approval secured, site mobilization underway, and new drilling planned to expand resources.

Hot Chili Limited has announced a non-renounceable entitlement offer aiming to raise approximately A$14 million to advance its strategic partnering efforts and drilling programs. Eligible shareholders can subscribe for new shares at 60 cents each, with funds earmarked for exploration and corporate purposes.

Vitrafy Life Sciences reported strong FY25 progress with 75% sales growth, advanced cryopreservation technology development, and a robust cash position. The company outlines a clear commercialisation roadmap for FY26, including product launches and expanded U.S. operations.

Credit Corp Group delivered a robust FY25 with a 16% increase in net profit after tax, driven by US debt buying and Australian/NZ lending growth. The company sets an ambitious FY26 outlook, underpinned by a record US investment pipeline and new product launches.

Noxopharm’s Sofra™ technology shows promising results in collaboration with US biotech Tezcat Biosciences, advancing targeted drug delivery for cancer and inflammatory diseases.

Hudson Investment Group faces intense scrutiny from ASX after its auditor issued a Disclaimer of Opinion on the 2024 financial report, citing doubts over a $2.4 million property receivable and the company’s going concern status.

Alterity Therapeutics faces ASX scrutiny after mistakenly marking multiple announcements as market sensitive, prompting a review of its disclosure practices. The biotech denies any intent to manipulate its share price despite repeated errors.

PT Aneka Tambang Tbk (ANTAM) has finalized a US$500 million loan facility to support its corporate initiatives, marking a significant material transaction disclosed under Indonesian financial regulations.